Citations

Clear

513 citation(s) found for "Ta, Casey".

The Clinical Pharmacist as Principal Investigator—2026
Buckley, Leo F. , Aljadeed, Raniah , Barreto, Jason N. , Greer, Samuel C., Kang, Amy , Laizure, S. Casey , Leino, Abbie D. , Moore, Darby , Nahata, Milap C. , Dixon, Dave L. , Baker, William L. , Greer, Samuel C. , MacLaren, Robert E. , Moore, Darby , Ng, Tien M. H. , Nguyen, Elaine

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 28, 2025 | Volume: 8 | Issue: 12 | Pages: 1362-1367

10.1002/jac5.70143 Get It

ABSTRACT The American College of Clinical Pharmacy (ACCP) first described the role and history of the pharmacist as principal investigator (PI) in 2000. An update was published in 2010, citing evidence from NIH and the ClinicalTrials.gov registry that showed an increase in the number of individuals with a Pharm.D. degree engaging in pharmacist‐directed research. The 2025 ACCP Publications Committee was charged with providing an update to the 2010 paper. Key findings include a substantial increase in the total amount of federal funding awarded to schools of pharmacy (SoP) between 2011 and 2023, a modest increase in the number of pharmacists receiving federal grants when comparing 2010 with 2024, and evidence of pharmacist leadership and engagement in Clinical and Translational Science Award networks and service on national grant review panels. It remains challenging, however, to ascertain accurate and reliable data on pharmacists serving in PI roles because of the limitations of currently available data sources. This is especially true for pharmacist PIs who receive non‐federal funding. Future opportunities include a continued emphasis on training programs to prepare pharmacists for PI roles, greater institutional support (e.g., research infrastructure, mentoring programs) for pharmacists serving in PI roles, better promotion of research career tracks to Pharm.D. students and trainees, enhanced efforts at SoP to pursue institutional training grants, and more collaborative efforts across professional organizations to advocate for pharmacist‐scientists. An urgent call to action is necessary to ensure the future growth and success of pharmacist‐directed research.
sEEG ‐guided responsive neurostimulation to treat neocortical epilepsy: A multicenter retrospective study of the efficacy and safety of depth electrode‐mediated neuromodulation
Sadeghzadeh, Sina , Purger, David , Bhanot, Priya , Johnson, Noriah , Schonfeld, Ethan , Abikenari, Matthew , Jain, Bhav , Aronson, Joshua P. , Drees, Cornelia , Fisher, Tiffany , Gray, Tyler E. , Ojemann, Steven , Sather, Michael D., Skidmore, Christopher , Yoo, Ji Yeoun , Graber, Kevin , Halpern, Casey H. , Buch, Vivek , Parker, Jonathon J. , Drees, Cornelia , Gray, Tyler E , Hines, Kevin , Karakis, Ioannis , Quraishi, Imran H , Raslan, Ahmed M , Wu, Chengyuan , Yoo, Ji Yeoun , Buch, Vivek , Skidmore, Christopher , Barbosa, Daniel A. N. , Huang, Yuhao , Park, Jay J. , Gerrard, Jason L. , Ghatan, Saadi , Jobst, Barbara C. , Karakis, Ioannis , Willie, Jon T , Wu, Chengyuan

Mayo Clinic

Epilepsia Open | November 18, 2025 | Volume: 11 | Issue: 1 | Pages: 146-161

10.1002/epi4.70180 | PMID 41251192 Get It

Abstract Objectives Pivotal trials have established the effectiveness of the Responsive Neurostimulation System (RNS® System) in treating focal epilepsy. In clinical trials, depth leads were primarily used to treat mesial temporal seizure onsets while cortical strip leads were used to treat neocortical seizure onsets. Here, we systematically analyze the safety and efficacy of stereoelectroencephalography (sEEG)‐guided depth leads to provide responsive stimulation to neocortical gray matter. Methods Patients were stratified as strong responders (>median cohort seizure reduction %), weak responders (>0% and ≤median cohort seizure reduction %), and anti‐responders (≤0%) based on percent seizure reduction at 1 year post‐implant (1‐Y). Pre‐operative T1‐weighted magnetic resonance imaging and post‐operative computed tomography images were merged, and the Euclidean distance between the sEEG epileptic focus (sEEG‐EF) and the nearest RNS System depth lead contacts was calculated. Results A total of 87 depth leads were implanted in 55 patients across neocortical brain regions. The median reduction in clinical seizures improved from 66.7% at 1‐Y to 77.5% at long‐term follow‐up (LTFU: 2.35 ± 0.95 years), with 10 patients (18.2%) achieving complete seizure freedom. Seven patients (12.7%) experienced six serious adverse events. At 1‐Y, shorter Euclidean distance between the sEEG‐EF and RNS System depth leads predicted improved seizure outcome in strong responders ( β = −0.84, p = 0.008) but not in weak responders ( β = 0.21, p = 0.9) or anti‐responders ( β = −20.34, p = 0.11). At LTFU, there was no significant relationship between Euclidean distance and seizure reduction in strong responders ( β = 0.77, p = 0.18), weak responders ( β = 2.05, p = 0.54), or anti‐responders ( β = 0.24, p = 0.99). Exploratory analyses at 1‐Y showed nominal associations between older age ( ρ = 0.32), longer epilepsy duration ( ρ = 0.27), and non‐mesial temporal sEEG‐EFs and greater seizure reduction; however, none survived Bonferroni correction (adjusted α = 0.0027; all post‐correction p > 0.0027), and no associations were observed at LTFU. Significance In this series, neocortical depth leads for RNS therapy had favorable safety and efficacy and proximity to the sEEG‐EF drove initial outcomes for strong responders to RNS therapy. Plain Language Summary In this multi‐center study, patients with difficult‐to‐treat seizures received brain‐responsive stimulation using a device called responsive neurostimulation (RNS), which delivers small electrical pulses to reduce seizures. We focused on patients treated with electrodes placed in the brain's outer regions (the neocortex) and guided by a mapping procedure called sEEG. On average, patients had their seizures cut by two‐thirds after one year and by more than three‐quarters with longer follow‐up, with about one in five becoming seizure‐free. The treatment was safe, and closer electrode placement to the seizure source helped explain early—but not long‐term—improvements.
Single Port Robotic Vascularized Omental Lymph Node Transfer for Lymphedema: A Novel Comparison to Open Technique
Jeger, Jonathan L. , Kandi, Lyndsay A. , Yi, Johnny , Jungbauer, W. Nicholas , Teven, Chad M. , Casey, William J., Rebecca, Alanna M. , Rebecca, Alanna, Jungbauer, Walter N , Jeger, Jonathan L

Mayo Clinic

Journal of Reconstructive Microsurgery | October 10, 2025 | Volume: 42 | Issue: 07 | Pages: 589-595

10.1055/a-2717-4610 | PMID 41072481 Get It

Abstract The da Vinci Single-Port (SP) system is a robotic surgery platform that allows access into the abdominal cavity through a single short surgical incision. The omentum is an attractive donor site for vascularized omental lymph node transfer (VOLT) in the treatment of lymphedema. We hypothesize that SP robotic VOLT will allow for improvement in perioperative outcomes as compared to open laparotomy for omental flap harvest. A retrospective cohort study was performed, comprised of a study sample of patients with a diagnosis of lymphedema who presented to our institution for VOLT using either an open or SP robotic technique between May 2020 and February 2023. The primary outcome was length of hospital stay. The secondary outcomes included intraoperative complication rate, postoperative complication rate, and length of surgery. Fifteen patients underwent da Vinci SP omental flap harvest, and 14 patients underwent open harvest. There was no significant difference in average age, BMI, sex, or lymphedema etiology between the two groups. Average length of stay was 2.2 ± 1.7 days in the SP group and 2.3 ± 2.1 days in the open group (p = 0.91). There were no significant differences in terms of intraoperative or postoperative complications between the two groups. Ninety-three percent of SP robotic and 86% of open patients reported at least partial subjective improvement following VOLT (p = 0.50). Our findings suggest that SP robotic omental harvest for VOLT is feasible. Perioperative outcomes show comparable results in terms of length of hospital stay, complications, and subjective postoperative improvement when comparing the open to the SP approach.
Lymphovenous Anastomosis and Vascularized Lymph Node Transfer Reduce Long-term Cellulitis Events in Patients With Secondary Lymphedema
Solomon, Santana, Verhey, Erik M., Jeger, Jonathan L. , Rhee, Daniel H. , Rebecca, Alanna M. , Saint-Cyr, Michel, Reece, Edward M., Casey, William J., Jungbauer, Walter N , Solomon, Santana, Jeger, Jonathan L , Chang, Yu‐Hui

Mayo Clinic

Annals of Plastic Surgery | October 10, 2025 | Volume: 95 | Issue: 5 | Pages: 522-530

10.1097/sap.0000000000004508 | PMID 41071856 Get It

Background Secondary lymphedema frequently occurs following surgery, malignancy, trauma, or radiation and is characterized by limb swelling, discomfort, and recurrent infections. Two advanced supermicrosurgical techniques—lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT)—have recently gained popularity as treatment options. However, long-term outcome data for these procedures remain limited. This systematic review and meta-analysis aim to evaluate the long-term efficacy of LVA and VLNT in patients with secondary lymphedema followed for more than 2 years postoperatively, focusing on outcomes such as cellulitis rates and limb circumference. Methods This study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria encompassed studies involving adult patients with secondary lymphedema treated with LVA or VLNT and with at least 24 months of follow-up. The primary outcomes were annual cellulitis incidence and limb circumference change, analyzed separately for upper and lower extremities. Meta-analysis was conducted using R version 4.3.1. Pooled effect sizes were estimated using random-effects models. Subgroup and sensitivity analyses were also performed. Results A total of 23 studies met the inclusion criteria, covering 648 limbs treated with either LVA (n = 216) or VLNT (n = 432). The weighted average patient age was 56.3 years, and the cohort was predominantly female (99.9%). For LVA, the pooled mean reduction in annual cellulitis events was −1.13 (95% confidence interval [CI], −1.70 to −0.57) for upper extremities and −1.32 (95% CI, −2.08 to −0.55) for lower extremities. VLNT yielded greater reductions in cellulitis, with pooled mean differences of −2.43 (95% CI, −3.36 to −1.50) and −1.38 (95% CI, −2.11 to −0.65) for upper and lower limbs, respectively. Additionally, VLNT reduced limb circumference by 42.7% (95% CI, 36.7–49.7) in upper extremities and 21.98% (95% CI, 19.8–24.4) in lower extremities. Conclusion LVA and VLNT both result in durable, long-term improvements in cellulitis rates, and VLNT was shown to reduce limb circumference. Given the significant impact on patient quality of life, these interventions should remain integral to the treatment algorithm for secondary lymphedema.
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
Bhattarai, Nirjan , Stevens, Ryan W. , Ilges, Dan , Robinson, John C. , Cole, Kristin C, O’Connell, Casey, Johnson, Tanner M , Ilges, Dan , O'Connell, Casey R, Johnson, Tanner M , Stevens, Ryan W , Wieruszewski, Patrick M. , Cole, Kristin C

Mayo Clinic

Journal of Antimicrobial Chemotherapy | October 9, 2025 | Volume: 81 | Issue: 1 | Pages: No page available

10.1093/jac/dkaf396 | PMID 41120249 Get It

Abstract Background Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behaviour, often resulting in subtherapeutic concentrations. Limited evidence suggests that posaconazole oral delayed-release (DR) tablets may be crushed. Methods This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum drug concentration drawn ≥5 days after posaconazole initiation. The primary outcome was attainment of therapeutic drug concentrations. Secondary outcomes included time to therapeutic serum concentration, adverse drug events, and frequency of occluded EFT. Results Of the included patients, 48 received IR suspension and 100 received DR tablets. Baseline characteristics and severity of illnesses were well balanced. Among IR suspension and crushed DR tablet recipients, 39% and 80% achieved therapeutic concentrations, respectively (P = 0.002). After adjusting for age, sex, BMI, drug interactions, posaconazole indication and malabsorptive conditions, crushed DR tablets were significantly more likely than IR suspension to achieve therapeutic posaconazole concentrations within 30 days (HR 5.22, 95% CI 2.35–11.61). Occluded EFTs were more frequent among crushed DR tablet recipients (27% versus 10%, P = 0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalaemia. Conclusions With EFT administration, crushed posaconazole DR tablets were associated with a greater likelihood of achieving therapeutic concentrations compared with IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation.
OMIP‐118 : A 38‐Marker Spectral Flow Cytometry Panel to Assess Human Regulatory T Cell Phenotype and Lineage Plasticity
Bhattacharya, Nilika, Hill, Jessica C., Copple, Kade, Nikhat, Sameena, Ager, Casey R. , Nikhat, Sameena , Jugler, Collin , Copple, Kade R, Ager, Casey R , Khosravi-Maharlooei, Mohsen

Mayo Clinic

Cytometry Part A | October 6, 2025 | Volume: 107 | Issue: 10 | Pages: 649-657

10.1002/cyto.a.24966 | PMID 41047584 Get It

ABSTRACT We report the optimization of a 38‐parameter spectral flow cytometry panel to identify, phenotype, and assess lineage plasticity of human regulatory T cells (Tregs). Tregs are an indispensable T cell lineage with pleiotropic tolerogenic functions whose activities contribute critically to numerous disease settings including cancer, autoimmunity, and infectious disease, among others. Phenotypic and functional heterogeneity within the Treg lineage has been appreciated, but the etiology and impact of Treg plasticity across disease states remain incompletely understood. Better tools are thus needed to deeply characterize human Treg phenotypic heterogeneity at the single cell level to advance discovery of Treg‐based biomarkers in disease and to assess the effects of Treg‐directed therapeutics. To this end, our 38‐parameter panel consists of a 13‐marker PBMC backbone module to broadly phenotype PBMCs while specifically discriminating Tregs, and a 25‐marker Treg phenotyping module to determine Treg differentiation state, activation profile, and lineage subtype. In contrast to many high‐parameter OMIPs that rely on surface staining only, we incorporated several intracellular targets in this panel. This afforded the opportunity to thoroughly evaluate binding characteristics of all antibodies in both pre‐fixation and post‐fixation and permeabilization settings; we identify several antibodies eligible for overnight post‐fixation staining that require substantially reduced titers as compared to traditional pre‐fixation staining, resulting in significant cost savings. Dimensionality reduction and semi‐supervised clustering on healthy donor PBMC‐derived Tregs profiled by our panel reveal up to 14 discrete Treg phenotypes. In sum, this panel enables deep phenotypic characterization of human Treg heterogeneity in peripheral blood specimens by spectral flow cytometry.
Implementing integrated genomic risk assessments for breast cancer: lessons learned from the Electronic Medical Records and Genomics study
Liu, Cong , Morse, Jennifer, Linder, Jodell E. , Antoniou, Antonis C. , Carver, Tim , Cortopassi, Josh , Peterson, Josh F. , Ta, Casey , Hoell, Christin , Prows, Cynthia A. , Miller, Emily , Perez, Emma , Jarvik, Gail P, Odgis, Jacqueline A. , Bonini, Katherine E. , McGuffin, Kyle, Maradik, Mary, Limdi, Nita, Marathe, Priya , Suckiel, Sabrina A. , Aguilar, Sienna , Lewis, Toni J., Wei, Wei‐Qi, Freimuth, Robert R, Håkonarson, Håkon , Wiesner, Georgia L. , Jarvik, Gail P. , Carver, Tim , Ta, Casey N , Hoell, Christin , Bland, Sarah T , Kottyan, Leah C , Luo, Yuan , Weng, Chunhua , Hakonarson, Hakon , Jarvik, Gail P , Liu, Cong , Peterson, Josh F , Crew, Katherine D. , Morse, Jennifer, Kenny, Eimear E , Bland, Harris T. , Mittendorf, Kathleen F. , McGuffin, Kyle, Kottyan, Leah C. , Abul‐Husn, Noura S. , Luo, Yuan , Freimuth, Robert R. , Weng, Chunhua , Chung, Wendy K.

Mayo Clinic

JAMIA Open | October 4, 2025 | Volume: 8 | Issue: 5 | Pages: No page available

10.1093/jamiaopen/ooaf113 | PMID 41140463 Get It

Abstract Objectives To implementation an automated multi-institutional pipeline that delivers breast-cancer risk integrated with polygenic risk scores, monogenic variants, family history, and clinical factors, emphasizing operational challenges and their solutions. Materials and Methods A five-stage process was executed at ten sites. Data streams from REDCap surveys, PRS and monogenic reports, and MeTree pedigrees were normalized and forwarded through a REDCap plug-in to the CanRisk API. Results Integrated risk was returned to >10 000 women; 3.6% were ≥25 % lifetime risk and 0.9% carried pathogenic variants. Pipeline generated score aligns well with manual generated ones. Major barriers such as heterogeneous pedigree formats, missing data, edge-case handling, and evolving model versions were identified and resolved through mapping rules, imputations, and iterative testing. Discussion Cross-platform data harmonization and stakeholder alignment were decisive for success. Borderline-risk communication and model-version drift remain open issues. Conclusion Large-scale PRS-integrated breast-cancer risk reporting is feasible but requires robust interoperability standards and iterative governance.
Evaluation of the Impact of Oral Ketamine on Opioid Requirements and Pain in Patients with Opioid Use Disorder: A Retrospective Review
Nabukenya, Antoinette, Uritsky, Tanya J., Beaudrie-Nunn, Aeryana, Pett, Danielle, Yagnala, Nikitha , Casey, Emily

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | September 8, 2025 | Volume: 39 | Issue: 3 | Pages: 448-448

10.1080/15360288.2025.2533685 Get It

Prehospital Workplace Violence (WPV) Dispatch Alerts: Anticipating Behavior and Preventing Violence
Arms, Kathryn J., Reiter, David T., Liedl, Chad P., Phillips, Jeffrey P., Clements, Casey M. , McGuire, Sarayna S. , Reiter, David T., Mullan, Aidan F.

Mayo Clinic

Prehospital Emergency Care | August 4, 2025 | Volume: 30 | Issue: 5 | Pages: 630-638

10.1080/10903127.2025.2542536 | PMID 40758828 Get It

An analysis of patient-reported outcomes among epidural steroid injection clinical trials
Khan, Adam , Ladd, Chase , Smith, Caleb J. , Douglas, A.G., Jacobsen, Sam, Otwell, Ryan, Pierce, Aaron, Relic, Aaron, Butler, Casey, Vassar, Matt, Roberts, Will , Douglas, Alexander, Jacobsen, Samuel M. , Hartwell, Micah L. , Khattab, Ahmad, Vassar, Matt B.

Mayo Clinic

Regional Anesthesia & Pain Medicine | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-106861

10.1136/rapm-2025-106861 | PMID 40659444 Get It